About Molecure S.A.

Marcin has over 15 years of experience in technology transfer, R&D project and life science investment management. He has been involved in preparation and management of more than 40 R&D and investment projects with a combined budget of over 200 million euro. He has founded and/or managed several life science start-ups, including Medicalgorithmics SA, where he was the CEO since its founding in 2005 until 2010. During that term he secured over 4 million PLN in private equity investment and over 4 million in matching public funds.

He was also responsible for business development and oversaw the first products cleared for marketing in Europe (CE mark, 2008, 2009) and USA (FDA 510k approval, 2009). Medicalgorithmics currently is listed on the Warsaw Stock Exchange (GPW, ticker MDG) with market capitalization over 1.2 billion PLN (300M USD) and high percentage of export sales. Marcin has been responsible for establishing a technology transfer platform within a bio-tech-med cluster (BTM Mazovia) formed around a 100 million euro Centre for Preclinical Research and Technology (CePT) investment project. The cluster brings together the three largest Warsaw universities, seven Polish Academy of Science institutes, several Polish biotech and biomed companies, VC and seed funds. He’s also a member of the GLG Institute. Since 2012 Marcin has also assisted the European Commission on independent expert panels performing the impact assessment and interim evaluations of the Innovative Medicines Initiative (IMI) the world’s largest public-private partnership (PPP) in pharmaceutical research.

Dr. Zbigniew Zasłona currently serves as Chief Scientific Officer at Molecure. He also manages the Department of Biology. He obtained his PhD in 2010 at the University of Giessen and the Marburg Lung Center in Germany, studying the mechanisms that modulate innate immunity in the context of pneumonia. He then undertook a postdoctoral fellowship at the University of Michigan in the USA, where he focused on pharmacological studies of GPCR receptors, in particular lipid mediators of inflammation. From 2015 to October 2020, he was a research fellow at Trinity College Dublin (Ireland) in the Department of Biochemistry and Immunology, as well as a Senior Investigator at the UK biotechnology company Sitryx (which in March 2020 entered into a $1 bln collaboration and license agreementacquired by Lillywith Eli Lilly), where he was responsible for anti-inflammatory drug development programs. Dr. Zasłona is a recognized international expert in the field of inflammatory processes and lung diseases and is repeatedly invited to lecture at leading international scientific conferences. 

Dr Piotr Iwanowski - graduated from the Medical University of Białystok with a degree in medicine and has held a PhD in medical sciences since 2010. He also completed postgraduate studies in medical law, bioethics, and medical sociology.

For over 20 years, Piotr Iwanowski has been supporting global clinical development, both as a managerial and executive employee (including as CMO) in pharmaceutical companies and organizations providing clinical research services (CRO), as well as running his own business, offering consulting services in this field.

Piotr Iwanowski has over 20 years of experience in medical practice, working both in healthcare institutions and running his own medical practice. He is also an independent expert in clinical research for the Medical Research Agency.

Piotr Iwanowski has been collaborating with Molecure since 2020.

Dr van der Horst has a strong track record of biotech business development having acted as lead negotiator in over 20 licensing and M&A transactions and raised over $1.3 billion through capital market transactions during his career.

Paul currently serves as Chief Business Officer at Agomab Therapeutics and prior to joining Agomab, he was Head of Corporate Development at Galapagos. In this role, he led all major transactions, investments, licensing and M&A activities, most notably, a key negotiator for Galapagos’ transformative $5bn strategic collaboration with Gilead Sciences.

From 2013 to 2016, Paul worked at Kempen & Co a boutique investment bank with specialist expertise in life sciences and healthcare, where he was responsible for transatlantic brokerage and investor transactions related to European pharmaceutical and biotech stocks.

Paul studied medicine and holds a PhD in Gynaecological Oncology from the Erasmus University Medical Centre in Rotterdam. Paul is a member of the Board of Directors at ImmuneTune.

Master’s degree from the University of Economics in Kraków, major in Management and Marketing (1994). A graduate of the University of Copenhagen, major in Business Relations Management (1992). D’Orsay Academy of Gastronomy and Wine 1990. From 1993, he was employed at Elektor Sp. z o.o. in Kraków. From 1994, he was the Regional Manager at REMY COINTREAU GROUP Polska. In 1995, he started working for COLGATE PALMOLIVE Polska, and from 2001 he was the Sales Manager at COLGATE PALMOLIVE Adria a.s. in the Balkans. From 2003, he was employed at Tchibo Polska as the Sales Director in the CEE region. In 2004, he joined SIGMA-KALON DECO Polska Sp. z o.o. as the Commercial Director, and a Member of the Management Board of the Polish company.

In 2007, he was appointed a Member of the Management Board of SIGMAKALON Deco Eastern a.s., and later of a part of PPG Europe in Prague where he was responsible for the operation of the commercial teams in Central & Eastern Europe and Africa (EMEA). From May 2008, he was associated with the Capital Group of Synthos S.A. as the Commercial Director, and later a Member of the Management Board responsible for managing the company’s commercial processes around the world. From July 2016, in the rank of Vice President of the Management Board, he was responsible for five business units, marketing and M&A projects. From June 2020, at FTF Columbus as the Managing Partner responsible for the Science and Technology sub-investment fund.

Agnieszka Motyl, MD, PhD, MBA

Expert with over 20 years of experience and extensive knowledge in the areas of business, change management, building company value, mergers, acquisitions and supporting organization development and synergies. In 2021, Agnieszka Motyl joined Black Forest Fund as a Business Partner. From 2021, she assisted the development of Hemolens Diagnostics as a member of the Supervisory Board of Hemolens Diagnostics, and from 2023 as a Member of the Management Board, ensuring the highest quality of services, products and technological solutions for both patients and doctors. Since 2021, Agnieszka has also been a member of the Supervisory Board of Hemolens Diagnostics B.V.

Dr Van Osselaer is an experienced global biopharmaceutical professional with over 25 years experience leading drug development projects at leading pharmaceutical companies. Nancy currently serves as an independent consultant for her company Why2What, which provides strategic implementation advice to biotech companies.

Nancy was previously Vice President Early Stage Development portfolio leader at Galapagos, where she was responsible for the strategy and development of early assets, including the cystic fibrosis program and various highly innovative assets in the immune-inflammation space. Before joining Galapagos, Nancy worked at UCB where she worked to identify better outcomes for neurology patients beyond the current treatment regimes.

Prior to this, Nancy spent over 17 years at Johnson and Johnson contributing to multiple registration files and participating in development review committees.

Nancy is a pharmacist by training and holds a PhD in pharmacology from the University of Antwerp, Belgium.​

Pawel Trawkowski is graduate of faculty of Marketing and Management of Warsaw University with 25 years of managerial experience and broad knowledge acquired in largest international pharmaceutical companies.

From 1997 to 2003 he was working in Abbott Laboratories Poland as Financial Controller. From 2003 to 2009 he was Finance Director and member of management board in polish affiliate of Wyeth, and after Pfizer acquisition of Wyeth he was Senior Strategist responsible for Business Development projects for Poland and CEE countries.

Since 2010 he works in Gilead Sciences where he had various roles in Europe and USA including leading global projects. Currently he is Vice President of Finance for ACE (Australia, Canada and Europe) Region. His responsibilities include oversight for all finance processes in the region, especially in area of financial planning, analysis and reporting for both Corporate and local markets.

Has almost 20 years’ experience in capital markets. During 1996-2000 he worked in the Department of Market Surveillance for the Securities and Exchange Commission (now the national Financial Supervision Authority) and as the Secretary of the Examination Commission for Investment Advisors. From 2000 to 2008 he worked in Pocztylion-Arka PTE SA as a Financial Controller and later as the Director of the Finance Department. From June 2008 till March 2011 he was employed by OPERA TFI SA, OPERA Dom Maklerski Sp. o.o. and OPERA-Kwiatkowski & Partners S.K.A. as Director of the Department of Finance & Accounting. He also served as Chief Financial Officer of the Brokerage Houses such as TMS Brokers S.A and FIT SA.

Slawek graduated from the University of Warsaw, Faculty of Marketing and Management, then finished postgraduate studies in enterprise value management at the Warsaw School of Economics in Warsaw, the Management 2008 course and Strategic Leadership Academy™ 2019 course at the Canadian International Management Institute and Harvard Business School Publishing.

Agnieszka Rajczuk-Szczepańska currently serves as the Human Resources (HR) Director at Molecure. She has over 25 years of experience in HR, including over 10 years in managerial positions. As HR Director, she is responsible for recruitment, on-boarding, motivation, training and employee development, competence assessment and talent development management, work efficiency management and building employee engagement. She is a graduate of the University of Wrocław in the field of psychology with a specialization in organization and management. She also completed post–graduate studies in human resources management and labor law at the Kozminski University in Warsaw. She is a co-founder of the Polish HR Association in Poland. 

During her studies in 2010-2013, she cooperated with the Institute of Experimental Biology M. Nencki PAN - initially as an intern, then as a specialist in the Department of International Cooperation and Project Management. From January 2014, she was a Manager, then Director of Operations, Director of Grants and Contracts, and currently Director of the Management Board Office at OncoArendi. Responsible for the comprehensive implementation of research and development projects financed from EU and domestic sources with a total value of over PLN 180 million. She also took an active part in the processes related to acquiring private capital, including making the Company public on the WSE in April 2018. Currently, she also coordinates activities related to communication and investor relations in the Company.

Maurycy graduated in Management and in Finance and Accounting from the Warsaw School of Economics (SGH). Maurycy has over 8 years of experience gained in various business analysis roles. He began his career at Amgen as a Business and Sales Analyst. Subsequently, at AstraZeneca, he held the position of Business Analyst in the Global Medical Excellence department, and later joined the Commercial Excellence department, expanding his knowledge in business strategy and analytics. Currently, as a Business Development Manager at Molecure, Maurycy oversees business development activities. His education in management, finance, and accounting, combined with practical experience in business analysis and development, contributes to driving strategic growth and operational excellence at Molecure.

He is a graduate of the University of Gent in Belgium, where he received his medical degree and PhD in 1993 and 1999. From 2002, he specialized in Pulmonary Medicine at Erasmus University in Rottterdam, where he became Professor of Lung Diseases in 2005. In 2007, he returned to Belgium obtaining an exceptional Odysseus Grant from the Flemish government and became Professor of Lung Diseases at the University of Gent. In 2012, he became director of the VIB Inflammatory Disease Research Center in Gent. He is the recipient of a prestigious ERC grant and is an editor for The Journal of Experimental Medicine, Mucosal Immunology and Trends in Immunology.

Bart Lambrecht has (co-)authored more than 200 scientific articles in the field of asthma and allergy. His team's research focuses on the role of dendritic cells in stimulating immune responses in the lung. In 2014, he was awarded the prestigious Francqui Prize for outstanding scientific achievements.

Luke O’Neill is Professor of Biochemistry in the School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute at Trinity College Dublin, Ireland. He is a world expert on innate immunity and inflammation. His main research interests include Toll-like receptors, Inflammasomes and Immunometabolism. He is listed by Thompson Reuters/ Clarivates in the top 1% of immunologists in the world, based on citations per paper. Professor O'Neill is co-founder of Sitryx Ltd, which aims to develop new medicines for inflammatory diseases. Another company he co-founded, Inflazome ,was recently acquired by Roche.

He was awarded the Royal Dublin Society / Irish Times Boyle Medal for scientific excellence, the Royal Irish Academy Gold Medal for Life Sciences, The Society for Leukocyte Biology (SLB) Dolph O. Adams award, the European Federation of Immunology Societies Medal, the Milstein Award of the International Cytokine and Interferon Society and the Landsteiner Award from the Austrian Academy of Sciences. He is a member of the Royal Irish Academy, EMBO (European Molecular Biology Organisation) and a Fellow of the Royal Society. 

Dr. Douglas W.P. Hay obtained his PhD in Physiology and Pharmacology from the University of Strathclyde, Scotland. Douglas is a Pharmaceutical Executive with more than 20 years in Drug Discovery, with particular expertise in respiratory and inflammatory disease therapeutic areas. Douglas joined GSK in 1985, and from 2001-2007 he was Vice President of the Chronic Obstructive Pulmonary Disease (COPD) Drug Discovery group within the Respiratory & Inflammation Centre of Excellence for Drug Discovery, leading over 80 staff. From 1985-2007 at GSK Douglas and staff identified more than 25 compounds selected for development, with 1 Approved, 1 NDA filed and 1 compound completing Phase III clinical trials. In 2007 Douglas joined Galleon Pharmaceuticals, a start-up company in Horsham, PA, as Senior Vice President, Drug Discovery, where in less than 6 months he built a high-quality team working on medicines for ventilator control conditions, such as sleep apnea. Douglas is recognized internationally as an expert in the area of respiratory science and therapeutics. He is author of over 100 peer-reviewed papers, more than 40 book chapters and reviews, and co-edited 2 books. Douglas is currently President of Hay Drug Discovery Consulting, LLC, which he formed in September, 2009.